89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, July 09, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, June 06, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket - AgriFORCE Growing Systems ( NASDAQ:AGRI ) , AGM Gr Hldgs ( NASDAQ:AGMH )
Shares of Vertiv Holdings Co VRT rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its full-year sales guidance. Vertiv reported quarterly earnings of 64 cents per share which beat the analyst consensus estimate ...
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its ...
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing ...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an ...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has ...
Dada Nexus, Titan Machinery, AT&T And Other Big Stocks Moving Higher On Monday - Dada Nexus ( NASDAQ:DADA ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of Dada Nexus Limited DADA rose sharply during Monday's session after the company received a preliminary, non-binding proposal from JD.com, Inc.
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Allakos ( NASDAQ:ALLK ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 600 points on Monday. Following the market opening Monday, the Dow traded down 0.33% to 44,276.05 while the NASDAQ fell 3.08% to 19,340.76. The S&P 500 also fell, dropping, 1.74% to 5,994.91.
New Strong Sell Stocks for January 7th
ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Nov. 29, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc.
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests ...
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing ...
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing ...
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis ( MASH ) at AASLD The Liver Meeting® 2024
SAN FRANCISCO, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that new analyses of data ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
SAN FRANCISCO, Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Aug. 09, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Appoints Francis Sarena as Chief Operating Officer
SAN FRANCISCO, Aug. 07, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, July 12, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
Is Madrigal Pharmaceuticals Stock a Buy?
The company could become a prominent player in the biotech industry, but that might take a while.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, June 14, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? - Eli Lilly and Co ( NYSE:LLY ) , Madrigal Pharmaceuticals ( NASDAQ:MDGL ) , Sagimet Biosciences ( NASDAQ:SGMT )
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc MDGL and Sagimet Biosciences Inc SGMT are trading lower. At the EASL International Liver Congress 2024, Eli Lilly And Co LLY shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, May 10, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, April 05, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis ( MASH ) with Fibrosis and Compensated Cirrhosis
-PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of ...
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, March 08, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the ...
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, March 08, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
LifeSci Search Elevates Leadership and Innovation in Life Sciences With Launch of New Advisory Board
NEW YORK, March 07, 2024 ( GLOBE NEWSWIRE ) -- LifeSci Search, a leading global executive search firm specializing in the healthcare sector, is proud to introduce its prestigious new advisory board.
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - 89bio ( NASDAQ:ETNB ) , IonQ ( NYSE:IONQ )
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
89bio to Participate in the Leerink Partners Global Biopharma Conference
SAN FRANCISCO, March 05, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's ...
Akero ( AKRO ) Up on Upbeat Week 96 Data From Liver Disease Study
Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Feb. 05, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key ... PR ...
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development - 89bio ( NASDAQ:ETNB )
RBC Capital Markets downgraded 89Bio Inc ETNB, a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for liver and cardio-metabolic diseases.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Dec. 19, 2023 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it ...
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Dec. 07, 2023 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing ...
Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - C3.ai ( NYSE:AI ) , Chewy ( NYSE:CHWY )
U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. CXM shares fell sharply in pre-market trading following weak earnings for the third quarter.
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Dec. 06, 2023 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has ...
89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease - 89bio ( NASDAQ:ETNB )
89bio Inc ETNB announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in nonalcoholic steatohepatitis ( NASH ) . The program will include two Phase 3 trials evaluating patients with NASH:
89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details - 89bio ( NASDAQ:ETNB )
89bio Inc ETNB released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis ( NASH ) .
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
SAN FRANCISCO, Nov. 21, 2023 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's ...
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic ( F4 ) Nonalcoholic Steatohepatitis ( NASH ) at AASLD The Liver Meeting® 2023
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated ... - Markets Insider ...
What's Going On With 89bio ( ETNB ) Stock Today - 89bio ( NASDAQ:ETNB )
Earlier today, Akero Therapeutics Inc AKRO reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin ( EFX ) in patients with compensated cirrhosis ( F4 ) due to nonalcoholic steatohepatitis ( NASH ) .
